TY - JOUR
T1 - The IDEAL framework for surgical robotics
T2 - development, comparative evaluation and long-term monitoring
AU - Marcus, Hani J.
AU - Ramirez, Pedro T.
AU - Khan, Danyal Z.
AU - Layard Horsfall, Hugo
AU - Hanrahan, John G.
AU - Williams, Simon C.
AU - Beard, David J.
AU - Bhat, Rani
AU - Catchpole, Ken
AU - Cook, Andrew
AU - Hutchison, Katrina
AU - Martin, Janet
AU - Melvin, Tom
AU - Stoyanov, Danail
AU - Rovers, Maroeska
AU - Raison, Nicholas
AU - Dasgupta, Prokar
AU - Noonan, David
AU - Stocken, Deborah
AU - Sturt, Georgia
AU - Vanhoestenberghe, Anne
AU - Vasey, Baptiste
AU - McCulloch, Peter
AU - Konge, Lars
AU - Grantcharov, Teodor
AU - Harji, Deena
AU - Ahmed, Kamran
AU - Sparrow, Rob
AU - Langley, Rebecca
AU - Kon, Alexander A.
AU - Goering, Sarah
AU - Evans, Len
AU - Draper, Heather
AU - Booth, Lesley
AU - Hutchinson, Katrina
AU - Grutters, Janneke
AU - Iglesias, Cynthia
AU - Corbacho, Belen
AU - Clifford, Tammy J.
AU - Clark, Alane
AU - Sampietro-Colom, Laura
AU - Maddern, Guy
AU - Scholte, Mirre
AU - Cohen, Tara
AU - Bisantz, Ann
AU - Cavuoto, Lora
AU - Yu, Denny
AU - Anger, Jennifer
AU - Skipworth, Richard
AU - Pickup, Laura
AU - The IDEAL Robotics Colloquium
N1 - Funding Information:
H.J.M. is supported by grants from the Wellcome (203145Z/16/Z) EPSRC (NS/A000050/1) Centre for Interventional and Surgical Sciences, National Institute for Health Research (NIHR) Biomedical Research Centre at University College London and the National Brain Appeal. H.J.M. also declares stocks in Panda Surgical, and has previously received consulting fees from Intuitive Ventures. D.Z.K. is supported by an NIHR Academic Clinical Fellowship and a Cancer Research UK Predoctoral Fellowship. J.G.H. is supported by an NIHR Academic Clinical Fellowship. D.J.B. holds a Royal College of Surgeons chair supported by the Rosetrees trust and declares institutional research grant funding from the NIHR. K.C. is financially supported by the Agency for Healthcare Research and Quality (grant no. R01 HS26491-01). A.C. is supported by NIHR funding from NIHR Health Technology Assessment, PGfAR, PHR, RfPB and i4i programs. K.H. is supported by a Discovery Project grant from the Australian Research Council (grant no. DP200100883) and an Australian Research Council Discovery Early Career Researcher Award (grant no. DE200101301). T.M. has acted as an unpaid advisory board member of Pumpinheart, and previously as senior medical officer in medical devices at the Health Products Regulatory Authority, Ireland, and previous co-chair of the Clinical Investigation and Evaluation Working Group of the European Commission. D. Stoyanov is supported by grants from the Wellcome Trust, UKRI, European Commission and RAEng and employment from Digital Surgery (Medtronic) and declares stocks in Odin Vision (Olympus) and Panda Surgical. M.R. is supported by grants from Siemens Healthineers and the Healthcare Institute in the Netherlands. P.D. is supported by grants from the UKRI, The Urology Foundation and the Recordati Foundation and declares consulting fees from Proximie, MysteryVibe and Jiva.AI. D.N. is the Chief Technology Officer of Moon Surgical. D. Stocken is supported by grants from NIHR, CRUK, YCR and BHF. D. Stocken declares traveling funding from RCSEng and AntiCancer Fund Belgium for conference attendance. G.S. is supported by a grant from the European Union Framework Programme (Horizon 2020). B.V. is supported by the Lord Florey scholarship (PhD scholarship) from the Berrow Foundation. P.M. receives grants from Medtronic and CMR (unrestricted educational grants to Oxford University for the IDEAL Collaboration) and the Oxford Biomedical Research Centre. J.C. is an associate medical director at CMR Surgical and receives a part-time salary from them.
Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - The next generation of surgical robotics is poised to disrupt healthcare systems worldwide, requiring new frameworks for evaluation. However, evaluation during a surgical robot’s development is challenging due to their complex evolving nature, potential for wider system disruption and integration with complementary technologies like artificial intelligence. Comparative clinical studies require attention to intervention context, learning curves and standardized outcomes. Long-term monitoring needs to transition toward collaborative, transparent and inclusive consortiums for real-world data collection. Here, the Idea, Development, Exploration, Assessment and Long-term monitoring (IDEAL) Robotics Colloquium proposes recommendations for evaluation during development, comparative study and clinical monitoring of surgical robots—providing practical recommendations for developers, clinicians, patients and healthcare systems. Multiple perspectives are considered, including economics, surgical training, human factors, ethics, patient perspectives and sustainability. Further work is needed on standardized metrics, health economic assessment models and global applicability of recommendations.
AB - The next generation of surgical robotics is poised to disrupt healthcare systems worldwide, requiring new frameworks for evaluation. However, evaluation during a surgical robot’s development is challenging due to their complex evolving nature, potential for wider system disruption and integration with complementary technologies like artificial intelligence. Comparative clinical studies require attention to intervention context, learning curves and standardized outcomes. Long-term monitoring needs to transition toward collaborative, transparent and inclusive consortiums for real-world data collection. Here, the Idea, Development, Exploration, Assessment and Long-term monitoring (IDEAL) Robotics Colloquium proposes recommendations for evaluation during development, comparative study and clinical monitoring of surgical robots—providing practical recommendations for developers, clinicians, patients and healthcare systems. Multiple perspectives are considered, including economics, surgical training, human factors, ethics, patient perspectives and sustainability. Further work is needed on standardized metrics, health economic assessment models and global applicability of recommendations.
U2 - 10.1038/s41591-023-02732-7
DO - 10.1038/s41591-023-02732-7
M3 - Article
SN - 1078-8956
VL - 30
SP - 61
EP - 75
JO - Nature Medicine
JF - Nature Medicine
IS - 1
ER -